Hope Biosciences has linked its stem cell therapy candidate to improved motor function in Parkinson’s disease patients in a phase 2 trial. The single-site study randomized 60 people with early to ...

Bristol Myers Squibb (NYSE: BMY) reinforces its hematology leadership through new research across multiple therapies for patients with lymphoma at the 67th American Society of Hematology (ASH) Annual ...

BENGALURU, Nov 14 (Reuters) - India put new privacy rules into force on Friday that will make Meta, Google, OpenAI and other companies minimize collection of personal data and give people more control ...

uniQure has acknowledged that what it called “game changing” data in September showing significant slowing of Huntington’s disease (HD) progression in patients treated with its gene therapy candidate ...

CAR T-cell therapies are individualized treatments approved for multiple hematologic malignancies, with improved management of adverse effects over time. Access to CAR T-cell therapies is limited by ...

Long-term safety and efficacy data have recently been published for a γ-retroviral gene therapy to treat ADA-SCID that is available as a fresh product in Milan (Strimvelis); 43 patients were treated ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. MCO-010 for retinitis pigmentosa is showing promise in ...

The Department of Labor is initiating an investigation into how the Bureau of Labor Statistics collects and reports “closely watched economic data,” according to a letter the department’s Assistant ...

uniQure's lead candidate AMT-130 targets Huntington's disease with promising clinical data and potential for accelerated FDA approval, driving my continued Buy rating. The company has strong cash ...

On Friday, REGENXBIO Inc. (NASDAQ:RGNX) shared new data from the Phase 1/2/3 CAMPSIITE trial of clemidsogene lanparvovec (RGX-121) for the treatment of patients with Mucopolysaccharidosis Type II (MPS ...